A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers

Divya Gupta, Ricky L. Owers, Mimi Kim, Dennis Yi-Shin Kuo, Gloria S. Huang, Shohreh Shahabi, Gary L. Goldberg, Mark H. Einstein

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objectives: A phase II trial designed to evaluate the safety and efficacy of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine or epithelial ovarian cancers. Methods: Eligible patients with recurrent epithelial ovarian or uterine cancers were treated with weekly topotecan 3.5 mg/m2 and docetaxel 30 mg/m2 for 3 consecutive weeks. Cycles were repeated every 4 weeks for 6 cycles or until evidence of disease progression, unacceptable toxicity, or death. Response was assessed as per RECIST or Rustin's criteria. Time to best response and overall survival were calculated using Kaplan-Meier statistical methods. Results: Twenty-seven patients registered, of which 24 were evaluable for response. The majority of patients had received 2 prior chemotherapy regimens. Of the total 86 cycles of chemotherapy that were administered, there were three grade 4 (all neutropenia) and ten grade 3 toxicities. Six of the grade 3 non-hematologic toxicities were unrelated to treatment. There were 8 dose delays and 4 dose reductions. The overall response rate was 25% (95% CI: 7.7%-42.3%, 8% CR, 17% PR), and 38% of the patients had clinical benefit (95% CI: 18.1%-56.9%; CR + PR + 13% SD). The median duration of response was 8.5 months (range 3-19 months). The median overall survival was 18.5 months (range 1.8-50.7 months). Conclusion: The combination of weekly topotecan and docetaxel has clinical benefit and is well tolerated in this heavily treated patient population. Patients with platinum-resistant tumors had clinical benefit and should be considered for further study with this regimen.

Original languageEnglish (US)
Pages (from-to)327-330
Number of pages4
JournalGynecologic Oncology
Volume113
Issue number3
DOIs
StatePublished - Jun 2009

Fingerprint

docetaxel
Topotecan
Uterine Neoplasms
Ovarian Neoplasms
Drug Therapy
Survival
Neutropenia
Platinum
Disease Progression

Keywords

  • Chemotherapy
  • Clinical trial
  • Docetaxel
  • Ovarian cancer
  • Topotecan
  • Uterine cancer

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers. / Gupta, Divya; Owers, Ricky L.; Kim, Mimi; Kuo, Dennis Yi-Shin; Huang, Gloria S.; Shahabi, Shohreh; Goldberg, Gary L.; Einstein, Mark H.

In: Gynecologic Oncology, Vol. 113, No. 3, 06.2009, p. 327-330.

Research output: Contribution to journalArticle

Gupta, Divya ; Owers, Ricky L. ; Kim, Mimi ; Kuo, Dennis Yi-Shin ; Huang, Gloria S. ; Shahabi, Shohreh ; Goldberg, Gary L. ; Einstein, Mark H. / A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers. In: Gynecologic Oncology. 2009 ; Vol. 113, No. 3. pp. 327-330.
@article{e7f3e097d2684aef88b76b0a9af8f9d5,
title = "A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers",
abstract = "Objectives: A phase II trial designed to evaluate the safety and efficacy of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine or epithelial ovarian cancers. Methods: Eligible patients with recurrent epithelial ovarian or uterine cancers were treated with weekly topotecan 3.5 mg/m2 and docetaxel 30 mg/m2 for 3 consecutive weeks. Cycles were repeated every 4 weeks for 6 cycles or until evidence of disease progression, unacceptable toxicity, or death. Response was assessed as per RECIST or Rustin's criteria. Time to best response and overall survival were calculated using Kaplan-Meier statistical methods. Results: Twenty-seven patients registered, of which 24 were evaluable for response. The majority of patients had received 2 prior chemotherapy regimens. Of the total 86 cycles of chemotherapy that were administered, there were three grade 4 (all neutropenia) and ten grade 3 toxicities. Six of the grade 3 non-hematologic toxicities were unrelated to treatment. There were 8 dose delays and 4 dose reductions. The overall response rate was 25{\%} (95{\%} CI: 7.7{\%}-42.3{\%}, 8{\%} CR, 17{\%} PR), and 38{\%} of the patients had clinical benefit (95{\%} CI: 18.1{\%}-56.9{\%}; CR + PR + 13{\%} SD). The median duration of response was 8.5 months (range 3-19 months). The median overall survival was 18.5 months (range 1.8-50.7 months). Conclusion: The combination of weekly topotecan and docetaxel has clinical benefit and is well tolerated in this heavily treated patient population. Patients with platinum-resistant tumors had clinical benefit and should be considered for further study with this regimen.",
keywords = "Chemotherapy, Clinical trial, Docetaxel, Ovarian cancer, Topotecan, Uterine cancer",
author = "Divya Gupta and Owers, {Ricky L.} and Mimi Kim and Kuo, {Dennis Yi-Shin} and Huang, {Gloria S.} and Shohreh Shahabi and Goldberg, {Gary L.} and Einstein, {Mark H.}",
year = "2009",
month = "6",
doi = "10.1016/j.ygyno.2009.02.018",
language = "English (US)",
volume = "113",
pages = "327--330",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers

AU - Gupta, Divya

AU - Owers, Ricky L.

AU - Kim, Mimi

AU - Kuo, Dennis Yi-Shin

AU - Huang, Gloria S.

AU - Shahabi, Shohreh

AU - Goldberg, Gary L.

AU - Einstein, Mark H.

PY - 2009/6

Y1 - 2009/6

N2 - Objectives: A phase II trial designed to evaluate the safety and efficacy of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine or epithelial ovarian cancers. Methods: Eligible patients with recurrent epithelial ovarian or uterine cancers were treated with weekly topotecan 3.5 mg/m2 and docetaxel 30 mg/m2 for 3 consecutive weeks. Cycles were repeated every 4 weeks for 6 cycles or until evidence of disease progression, unacceptable toxicity, or death. Response was assessed as per RECIST or Rustin's criteria. Time to best response and overall survival were calculated using Kaplan-Meier statistical methods. Results: Twenty-seven patients registered, of which 24 were evaluable for response. The majority of patients had received 2 prior chemotherapy regimens. Of the total 86 cycles of chemotherapy that were administered, there were three grade 4 (all neutropenia) and ten grade 3 toxicities. Six of the grade 3 non-hematologic toxicities were unrelated to treatment. There were 8 dose delays and 4 dose reductions. The overall response rate was 25% (95% CI: 7.7%-42.3%, 8% CR, 17% PR), and 38% of the patients had clinical benefit (95% CI: 18.1%-56.9%; CR + PR + 13% SD). The median duration of response was 8.5 months (range 3-19 months). The median overall survival was 18.5 months (range 1.8-50.7 months). Conclusion: The combination of weekly topotecan and docetaxel has clinical benefit and is well tolerated in this heavily treated patient population. Patients with platinum-resistant tumors had clinical benefit and should be considered for further study with this regimen.

AB - Objectives: A phase II trial designed to evaluate the safety and efficacy of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine or epithelial ovarian cancers. Methods: Eligible patients with recurrent epithelial ovarian or uterine cancers were treated with weekly topotecan 3.5 mg/m2 and docetaxel 30 mg/m2 for 3 consecutive weeks. Cycles were repeated every 4 weeks for 6 cycles or until evidence of disease progression, unacceptable toxicity, or death. Response was assessed as per RECIST or Rustin's criteria. Time to best response and overall survival were calculated using Kaplan-Meier statistical methods. Results: Twenty-seven patients registered, of which 24 were evaluable for response. The majority of patients had received 2 prior chemotherapy regimens. Of the total 86 cycles of chemotherapy that were administered, there were three grade 4 (all neutropenia) and ten grade 3 toxicities. Six of the grade 3 non-hematologic toxicities were unrelated to treatment. There were 8 dose delays and 4 dose reductions. The overall response rate was 25% (95% CI: 7.7%-42.3%, 8% CR, 17% PR), and 38% of the patients had clinical benefit (95% CI: 18.1%-56.9%; CR + PR + 13% SD). The median duration of response was 8.5 months (range 3-19 months). The median overall survival was 18.5 months (range 1.8-50.7 months). Conclusion: The combination of weekly topotecan and docetaxel has clinical benefit and is well tolerated in this heavily treated patient population. Patients with platinum-resistant tumors had clinical benefit and should be considered for further study with this regimen.

KW - Chemotherapy

KW - Clinical trial

KW - Docetaxel

KW - Ovarian cancer

KW - Topotecan

KW - Uterine cancer

UR - http://www.scopus.com/inward/record.url?scp=67349180185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349180185&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2009.02.018

DO - 10.1016/j.ygyno.2009.02.018

M3 - Article

VL - 113

SP - 327

EP - 330

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -